drugset / Trial / NCT06083922
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Phase 2
Recruiting
20 enrolled
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.
Timeline
- Start
- 2023-10-16
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Dexamethasone | Small molecule | — | — |